# Characterizing Public Comments on Cannabis Rescheduling via Regulations.gov > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-rescheduling-public-comments-analysis-2024/ > **Published:** 2026-04-24T13:08:42-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:12:11-04:00 > **Clinical Summary:** Explore cannabis rescheduling public comments from Regulations.gov revealing stakeholder views on DEA's proposed Schedule III change in 2024. --- CED Clinical Relevance  #56Monitored Relevance  Early-stage or contextual signal requiring further evidence before action. 🔬 Evidence Watch  |  CED Clinic PolicyRegulation[Medical Cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/)Patient AccessPublic Health Journal Addiction (Abingdon, England) Study Type Clinical Study Population Human participants Why This Matters This analysis of over 42,000 public comments provides unprecedented insight into public sentiment regarding cannabis rescheduling, which directly impacts patient access to [cannabis-based treatments](https://cedclinic.com/cannabis-medical-clinic-experience-beyond-smoking-vaping/). Understanding stakeholder perspectives helps clinicians anticipate regulatory changes and patient expectations around medical cannabis availability. Clinical Summary Researchers conducted a mixed-methods analysis of public comments submitted to Regulations.gov between May and July 2024 regarding the DEA’s proposal to reschedule cannabis from Schedule I to Schedule III. The study examined 42,913 comments using both manual review and automated natural language processing to categorize sentiment (support, oppose, or insufficient rescheduling) and identify thematic justifications. This represents the largest systematic analysis of public input on cannabis policy reform to date, though the study is limited by potential selection bias in who submits public comments and the brief comment period analyzed. Dr. Caplan’s Take “While this policy analysis doesn’t change my clinical practice directly, it helps me understand the public discourse my patients are navigating. The volume and nature of these comments likely influenced the ongoing rescheduling process that affects patient access to cannabis medicines.” Clinical Perspective 🧠 Clinicians should be prepared to discuss rescheduling implications with patients who may have heightened expectations about cannabis access and legitimacy. This data suggests significant public engagement with cannabis policy, indicating patients are actively following these developments and may seek guidance on how regulatory changes affect their treatment options. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Characterizing%20public%20comments%20via%20Regulations.gov%20in%20response%20to%20proposed%20canna...%20%40drcaplan&url=https%3A//pubmed.ncbi.nlm.nih.gov/42029003/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//pubmed.ncbi.nlm.nih.gov/42029003/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Characterizing%20public%20comments%20via%20Regulations.gov%20in%20response%20to%20proposed%20canna...%20--%20via%20%40drcaplan.bsky.social%20https%3A//pubmed.ncbi.nlm.nih.gov/42029003/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/42029003/](https://pubmed.ncbi.nlm.nih.gov/42029003/) Table of Contents - [FAQ](#FAQ)[What does rescheduling cannabis from Schedule I to Schedule III mean for medical practice?](#What_does_rescheduling_cannabis_from_Schedule_I_to_Schedule_III_mean_for_medical_practice) - [How might cannabis rescheduling affect patient access to medical cannabis?](#How_might_cannabis_rescheduling_affect_patient_access_to_medical_cannabis) - [What are the main arguments healthcare stakeholders are making about cannabis rescheduling?](#What_are_the_main_arguments_healthcare_stakeholders_are_making_about_cannabis_rescheduling) - [Will rescheduling to Schedule III resolve current research limitations on cannabis?](#Will_rescheduling_to_Schedule_III_resolve_current_research_limitations_on_cannabis) - [How should clinicians interpret this public policy development for their practice?](#How_should_clinicians_interpret_this_public_policy_development_for_their_practice) - [Related](#Related) ## FAQ #### What does rescheduling cannabis from Schedule I to Schedule III mean for medical practice? Rescheduling cannabis from Schedule I to Schedule III would acknowledge its accepted medical use and lower abuse potential compared to Schedule I substances. This change would reduce regulatory barriers for research and potentially expand legitimate medical access, though cannabis would still remain a controlled substance with federal oversight. #### How might cannabis rescheduling affect patient access to medical cannabis? Rescheduling to Schedule III could improve patient access by reducing some federal restrictions and potentially allowing more research into therapeutic applications. However, the analysis of over 42,000 public comments suggests many stakeholders believe this rescheduling is insufficient to fully address current access barriers. #### What are the main arguments healthcare stakeholders are making about cannabis rescheduling? Based on the public comment analysis, stakeholders express varied perspectives ranging from support for any rescheduling progress to opposition or calls for more comprehensive reform. The study identified underlying justifications that likely include medical efficacy, patient safety concerns, and access issues, though specific clinical arguments require detailed comment analysis. #### Will rescheduling to Schedule III resolve current research limitations on cannabis? While Schedule III classification would reduce some research barriers compared to Schedule I, significant regulatory oversight would remain. The public sentiment analysis suggests the research community may view this as a positive but potentially insufficient step toward enabling comprehensive clinical studies of cannabis therapeutics. #### How should clinicians interpret this public policy development for their practice? This represents an early-stage policy signal that requires monitoring but not immediate practice changes. Clinicians should stay informed about the evolving regulatory landscape while continuing to follow current state and federal guidelines regarding medical cannabis recommendations and patient counseling. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Cannabis Schedule III Rescheduling Impact on Medical Research and Patients](https://cedclinic.com/cannabis-schedule-iii-rescheduling-research-impact-patients/) Explore how the Schedule III rescheduling of cannabis affects [medical research](https://cedclinic.com/cb2-receptor-agonist-parkinsons/) opportunities and patient access to therapies. [Read More](https://cedclinic.com/cannabis-schedule-iii-rescheduling-research-impact-patients/) [Avicanna Welcomes Initial U.S. Rescheduling of Medical Cannabis & Provides Scientific Update](https://cedclinic.com/cannabis-rescheduling-clinical-research-implications/) Scientific insights on the implications of cannabis rescheduling for [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) and therapeutic development. [Discover Insights](https://cedclinic.com/cannabis-rescheduling-clinical-research-implications/) [Reclassification of marijuana opens doors for much-needed medical research into the … – Seattle PI](https://cedclinic.com/cannabis-reclassification-medical-research-barriers-schedule-three/) An overview of how marijuana reclassification to Schedule III may reduce research barriers and expand medical studies. [Learn More](https://cedclinic.com/cannabis-reclassification-medical-research-barriers-schedule-three/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).